SEARCH

SEARCH BY CITATION

References

  • 1
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 25572576.
  • 2
    Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006; 60: 8998.
  • 3
    Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR. Genetics of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 22712282.
  • 4
    Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843854.
  • 5
    Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215233.
  • 6
    Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99: 1552415529.
  • 7
    O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839843.
  • 8
    Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682688.
  • 9
    Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 21282136.
  • 10
    Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, et al. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 2008; 28: 53695380.
  • 11
    Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 25372545.
  • 12
    Jiang J, Gusev Y, Aderca I, Mettler TA, Nagorney DM, Brackett DJ, et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 14: 419427.
  • 13
    Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, et al. Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. HEPATOLOGY 2009; 49: 10981112.
  • 14
    Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. HEPATOLOGY 2008; 47: 19551963.
  • 15
    Li W, Xie L, He X, Li J, Tu K, Wei L, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008; 123: 16161622.
  • 16
    Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. HEPATOLOGY 2008; 47: 897907.
  • 17
    Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu CG, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 60926099.
  • 18
    Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 11351142.
  • 19
    Li S, Fu H, Wang Y, Tie Y, Xing R, Zhu J, et al. MicroRNA-101 regulates expression of the v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) oncogene in human hepatocellular carcinoma. HEPATOLOGY 2009; 49: 11941202.
  • 20
    Liu S LD. Relationship between the expression of uPAR and invasion and metasitasis of hepatocellular carcinoma. Su Zhou University J Medical Science 2008; 28: 791793.
  • 21
    Xie Q, Liu K, Hu M, Wu X, Zhou K. Influence of scatter factor/hepatocyte growth factor on the growth and transmission of hepatocarcinoma SMMC 7721 cells. Zhonghua Gan Zang Bing Za Zhi 2001; 9: 9597.
  • 22
    Jin S, Pan X, Wang Y. Effect of nm23H1 on proliferation, tumor formation and metastasis of hepatocarcinoma. Zhonghua Zhong Liu Za Zhi 2000; 22: 381384.
  • 23
    Davis MG, Kawai Y, Arinze IJ. Involvement of Gialpha2 in sodium butyrate-induced erythroblastic differentiation of K562 cells. Biochem J 2000; 346: 455461.
  • 24
    Watkins DC, Johnson GL, Malbon CC. Regulation of the differentiation of teratocarcinoma cells into primitive endoderm by G alpha i2. Science 1992; 258: 13731375.
  • 25
    Hermouet S, Aznavoorian S, Spiegel AM. In vitro and in vivo growth inhibition of murine melanoma K-1735 cell by a dominant negative mutant alpha subunit of the Gi2 protein. Cell Signal 1996; 8: 159166.
  • 26
    Dhanasekaran N, Tsim ST, Dermott JM, Onesime D. Regulation of cell proliferation by G proteins. Oncogene 1998; 17: 13831394.
  • 27
    Faivre S, Regnauld K, Bruyneel E, Nguyen QD, Mareel M, Emami S, et al. Suppression of cellular invasion by activated G-protein subunits Galphao, Galphai1, Galphai2, and Galphai3 and sequestration of Gbetagamma. Mol Pharmacol 2001; 60: 363372.
  • 28
    Tang ZY. Hepatocellular carcinoma—cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445454.
  • 29
    Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007; 133: 647658.
  • 30
    Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW, Chen CM, et al. MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. HEPATOLOGY 2009; 49: 15711582.
  • 31
    Schlaeger C, Longerich T, Schiller C, Bewerunge P, Mehrabi A, Toedt G, et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. HEPATOLOGY 2008; 47: 511520.
  • 32
    Zhang LH, Qin LX, Ma ZC, Ye SL, Liu YK, Ye QH, et al. Allelic imbalance regions on chromosomes 8p, 17p and 19p related to metastasis of hepatocellular carcinoma: comparison between matched primary and metastatic lesions in 22 patients by genome-wide microsatellite analysis. J Cancer Res Clin Oncol 2003; 129: 279286.
  • 33
    Hand NJ, Master ZR, Eauclaire SF, Weinblatt DE, Matthews RP, Friedman JR. The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 2009; 136: 10811090.
  • 34
    Bruchova H, Merkerova M, Prchal JT. Aberrant expression of microRNA in polycythemia vera. Haematologica 2008; 93: 10091016.
  • 35
    Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008; 111: 478486.
  • 36
    Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009; 104: 170178, 6p following 178.
  • 37
    Wu F, Zhu S, Ding Y, Beck WT, Mo YY. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clin Cancer Res 2009; 15: 15501557.
  • 38
    Tang X, Muniappan L, Tang G, Ozcan S. Identification of glucose-regulated miRNAs from pancreatic {beta} cells reveals a role for miR-30d in insulin transcription. RNA 2009; 15: 287293.
  • 39
    Marton S, Garcia MR, Robello C, Persson H, Trajtenberg F, Pritsch O, et al. Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 2008; 22: 330338.
  • 40
    Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007; 26: 75907595.
  • 41
    Sartori M, Ceolotto G, Dorigatti F, Mos L, Santonastaso M, Bratti P, et al. RGS2 C1114G polymorphism and body weight gain in hypertensive patients. Metabolism 2008; 57: 421427.
  • 42
    Baculikova M, Fiala R, Jezova D, Macho L, Zorad S. Rats with monosodium glutamate-induced obesity and insulin resistance exhibit low expression of Galpha(i2) G-protein. Gen Physiol Biophys 2008; 27: 222226.
  • 43
    Pena JA, Thompson-Snipes L, Calkins PR, Tatevian N, Puppi M, Finegold MJ. Alterations in myeloid dendritic cell innate immune responses in the Galphai2-deficient mouse model of colitis. Inflamm Bowel Dis 2009; 15: 248260.
  • 44
    Lai L, Yuan L, Chen Q, Dong C, Mao L, Rowan B, et al. The Galphai and Galphaq proteins mediate the effects of melatonin on steroid/thyroid hormone receptor transcriptional activity and breast cancer cell proliferation. J Pineal Res 2008; 45: 476488.
  • 45
    Langlois S, Gingras D, Beliveau R. Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation. Blood 2004; 103: 30203028.
  • 46
    Zhang WJ, Koltun WA, Tilberg AF, Page MJ, Chorney MJ. Absence of GNAI2 codon 179 oncogene mutations in inflammatory bowel disease. Inflamm Bowel Dis 2000; 6: 103106.
  • 47
    Peters DG, Kudla DM, Deloia JA, Chu TJ, Fairfull L, Edwards RP, et al. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression. Cancer Epidemiol Biomarkers Prev 2005; 14: 17171723.